BioNTech Management
Management criteria checks 4/4
BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.83 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.23% of the company’s shares, worth $4.67B. The average tenure of the management team and the board of directors is 3.3 years and 4.6 years respectively.
Key information
Ugur Sahin
Chief executive officer
€3.1m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 16.8yrs |
| CEO ownership | 17.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Nov 06BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates
Nov 06
BioNTech's Oncology Gamble: High Stakes, Big Potential
Oct 21BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -€467m |
| Jun 30 2024 | n/a | n/a | -€504m |
| Mar 31 2024 | n/a | n/a | €113m |
| Dec 31 2023 | €3m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
| Sep 30 2019 | n/a | n/a | -€122m |
| Jun 30 2019 | n/a | n/a | -€116m |
| Mar 31 2019 | n/a | n/a | -€77m |
| Dec 31 2018 | €653k | €210k | -€48m |
Compensation vs Market: Ugur's total compensation ($USD3.18M) is below average for companies of similar size in the US market ($USD12.66M).
Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.
CEO
Ugur Sahin (59 yo)
16.8yrs
Tenure
€3,056,000
Compensation
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 16.8yrs | €3.06m | 17.23% $ 4.7b | |
| Co-Founder | 6.8yrs | €814.00k | 0.38% $ 103.3m | |
| CFO & Member of Management Board | 3.3yrs | €1.32m | 0.00068% $ 184.4k | |
| MD, COO & Member of Management Board | 10.8yrs | €821.00k | 0.31% $ 85.4m | |
| Chief Strategy Officer | 4.8yrs | €1.41m | 0.0061% $ 1.7m | |
| Chief Legal & Business Officer & Member of the Management Board | 1.2yrs | €848.00k | no data | |
| Executive Officer | less than a year | €133.00k | 0.34% $ 92.2m | |
| Senior Vice President of Global Financial Reporting & Accounting | less than a year | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | less than a year | no data | no data | |
| Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | no data | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | no data | no data |
3.3yrs
Average Tenure
57yo
Average Age
Experienced Management: BNTX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Supervisory Board Member | 2.4yrs | €90.00k | 0.00017% $ 46.1k | |
| Independent Deputy Chairman Supervisory Board | 6.8yrs | €114.00k | no data | |
| Independent Supervisory Board Member | 16.8yrs | €80.00k | no data | |
| Independent Supervisory Board Chairman | 16.8yrs | €226.00k | 0.14% $ 37.6m | |
| Member of Supervisory Board | 1.5yrs | €46.00k | no data | |
| Supervisory Board Member | 2.4yrs | €105.00k | 0.00010% $ 27.1k |
4.6yrs
Average Tenure
58.5yo
Average Age
Experienced Board: BNTX's board of directors are considered experienced (4.6 years average tenure).